Dexamphetamine Use for Management of Obesity and Hypersomnolence Following Hypothalamic Injury
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
UNLABELLED: Unrelenting weight gain, morbid obesity and disturbance of the sleep-wake cycle are well-recognized sequelae of hypothalamic injury. These health problems and their risk of significant associated co-morbidity drive the search for potential treatment modalities. OBJECTIVE: To report effects on weight change and wakefulness in a cohort of 12 patients with structural hypothalamic lesions treated with low-dose dexamphetamine. METHOD: Retrospective review of case notes. RESULTS: Twelve patients received dexamphetamine 5 mg twice daily (median duration 13 months in males, 15 months in females). Ten of 12 patients experienced either stabilisation of weight or weight loss on treatment (median loss -0.7 SDS in males, -0.44 SDS in females). Eleven patients reported improvement in daytime wakefulness and/or concentration and exercise tolerance. CONCLUSION: Low-dose dexamphetamine therapy has a positive impact on inexorable weight gain and daytime somnolence following hypothalamic injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight
Kalra, S. P. (1999) · Endocrine Reviews · doi:10.1210/er.20.1.68 · Cited by 1,554
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Features of the metabolic syndrome after childhood craniopharyngioma
Srinivasan, S., Ogle, G. D., Garnett, S. P., Briody, J. N., Lee, J. W., & Cowell, C. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030442 · Cited by 211
Slowing of growth in height and weight on stimulants: A characteristic pattern
Poulton, A., & Cowell, C. (2003) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2003.00107.x · Cited by 132
Cited by
10.1016/b978-1-4160-2911-3.50026-1
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/b978-1-4160-2911-3.50026-1 · Cited by 554
Müller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J.-P., & Puget, S. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0125-9 · Cited by 515
Müller, H. L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1115 · Cited by 401
European guidelines on managing adverse effects of medication for ADHD
(for the European Guidelines Group), Graham, J., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R. W., Döpfner, M., Hamilton, R., Hollis, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-010-0140-6 · Cited by 374
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt-Hansen, J., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0972 · Cited by 43
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
“85,86,91 A pilot study of caffeine and ephedrine given to three individuals with HO resulted in a mean weight loss of 14%, with two sustaining weight loss for at least 2 years; however, long-term safety, particularly in the paediatric population, is unknown.”
BackgroundA Novel Rodent Model That Mimics the Metabolic Sequelae of Obese Craniopharyngioma Patients
Roth, C. L., Blevins, J. E., Ralston, M., Elfers, C., Ogimoto, K., Kaiyala, K. J., & Morton, G. J. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182083b67 · Cited by 35
Dextroamphetamine Treatment in Children With Hypothalamic Obesity
van Schaik, J., Welling, M. S., de Groot, C. J., van Eck, J. P., Juriaans, A., Burghard, M., Oude Ophuis, S. B. J., Bakker, B., Tissing, W. J. E., Schouten-van Meeteren, A. Y. N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.845937 · Cited by 30
“reported weight reduction or stabilization in 10 out of 12 children and in 11 out of 12 children an improvement of subjectively reported daytime somnolence possibly leading to increased mobility (27).”
BackgroundPerez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29
Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update
Romigi, A., Feola, T., Cappellano, S., De Angelis, M., Pio, G., Caccamo, M., Testa, F., Vitrani, G., Centonze, D., Colonnese, C., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.817257 · Cited by 28
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
“It is noteworthy that those patients who withdraw from treatment due to gastro-intestinal side effects or the cost of the medication (only partly covered by subsidy) all rapidly re-gained weight (data not shown), underlining the importance of continuous treatment for sustained weight management In…”
BackgroundMethylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity
Horne, V. E., Bielamowicz, K., Nguyen, J., Hilsenbeck, S., Lindsay, H., Sonabend, R., Wood, A. C., Okcu, F., & Sisley, S. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28379 · Cited by 20
Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review
Cordani, R., Veneruso, M., Napoli, F., Di Iorgi, N., Milanaccio, C., Consales, A., Disma, N., De Grandis, E., Maghnie, M., & Nobili, L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.876011 · Cited by 15
Multidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study
Tessaris, D., Matarazzo, P., Tuli, G., Tuscano, A., Rabbone, I., Spinardi, A., Lezo, A., Fenocchio, G., Buganza, R., & de Sanctis, L. (2021) · Children · doi:10.3390/children8070531 · Cited by 11
Metadata
- Authors
- Ismail, O'Connell, & Zacharin
- Venue
- Journal of Pediatric Endocrinology and Metabolism
- Publisher
- Walter de Gruyter GmbH
- Published
- 2006-02
- Volume
- 19
- Issue
- 2
- Pages
- 129-134
- ISSN
- 0334-018X (ISSN-L)
- 2191-0251
- OpenAlex
- W1976921443
- Cited by
- 81
- References
- 4
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.